Skip to ContentSkip to Navigation
About us Practical matters How to find us prof. dr. E. (Edwin) Bremer


Direct Functionalization of Polysaccharide-Based Xylan Phenyl Carbonate Nanoparticles with Tumor Cell Specific Antibodies

Novel high-yield potato protease inhibitor panels block a wide array of proteases involved in viral infection and crucial tissue damage

A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for in vitro screening of immunomodulatory checkpoints and therapeutics

Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit

EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells

Galectin-9 has non-apoptotic cytotoxic activity toward acute myeloid leukemia independent of cytarabine resistance

Notch1 promotes resistance to cisplatin by up-regulating Ecto-5'-nucleotidase (CD73) in triple-negative breast cancer cells

Salivary extracellular miRNAs for early detection and prognostication of esophageal cancer: a clinical study

Signal regulatory protein beta 2 is a novel positive regulator of innate anticancer immunity

The DNA damage response pathway regulates the expression of the immune checkpoint CD47

Read more


Groningse CAR-T-celtherapie krijgt KWF-subsidie

2,6 miljoen subsidie voor revolutionair oncologie onderzoek

Miljoenensubsidie voor UMCG-onderzoek naar therapie voor uitbehandelde kankerpatiënten

UMCG ontvangt grote EU-subsidie voor onderzoek naar nieuwe immuuntherapie bij kanker

Grote EU-subsidie voor UMCG voor onderzoek naar CAR-T immuuntherapie bij kanker

Ruim 5 miljoen voor uniek Nederlands platform voor gen- en celtherapie

Ruim 5 miljoen voor cel- en gentherapie


Read more